Companies / Germany
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Sanofi-Aventis Receives Plavix Blow
January 2007 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
French drug giant Sanofi-Aventis has frozen investment at its Hoesht facility in Germany after the country's healthcare committee, the GBA, refused to reimburse its blockbuster cardiovascular drug Plavix (clopidogrel) for certain patient groups. BMI believes that Sanofi's decision is representative of the risks that an overtly cost-conscious public health policy can have on a country's pharmaceutical industry.